newsfilter
← Latest News
GlobeNewswire·

NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million